BioSpace News Archive

BioMidwest

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

The novel non-DES, non-BMS COBRA PzF NanoCoated Coronary Stent (NCS) with just 14-days DAPT demonstrated statistically less bleeding (BARC 1-5) compared to the DES arm at 3 or 6 months DAPT post-PCI, low 0.6% ST and low 3.7% ischemic-driven TLR at 6 months.

October 17, 2020
·
6 min read
Policy

Statement from the Chief Public Health Officer of Canada on October 17, 2020

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

October 17, 2020
·
2 min read
Emapalumab’s efficacy confirmed by sensitivity analysis presented at ESID2020

All analyses support the primary endpoint efficacy of a 63 per cent overall response rate (ORR) in patients with insufficient response to standard of care in the pivotal study.

October 17, 2020
·
4 min read
Policy

Dr. Reddy’s and RDIF receive approval to conduct clinical trial for Sputnik V vaccine in India

Dr. Reddy’s Laboratories Ltd. and Russian Direct Investment Fund, Russia’s sovereign wealth fund, announced that they have received approval from the Drug Control General of India to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India.

October 17, 2020
·
3 min read
Pharm Country

OPTIMIZE Study Reports Lowest TLR Ever Achieved in an Investigational Device Exemption (IDE) Study With Svelte Medical System’s Bioresorbable Coated Drug-Eluting Coronary Stent

The Svelte® Drug-Eluting Stent achieved 1.5% clinically-driven Target Lesion Revascularization at 1 year, the lowest ever reported in an Investigational Device Exemption clinical study.

October 17, 2020
·
5 min read